SpectRx, Inc. Successfully Builds And Tests First Pre-Production Non-Invasive Cervical Cancer Detection Device

NORCROSS, Ga.--(BUSINESS WIRE)--Jan. 4, 2006--SpectRx, Inc. (OTCBB: SPRX) today announced that it successfully built and tested its first pre-production non-invasive cervical cancer detection device. The next-generation device contains major components planned for use in commercial production and is to be used to complete the ongoing U.S. Food and Drug Administration (FDA) pivotal clinical trial necessary for regulatory approval.
MORE ON THIS TOPIC